

SHORT COMMUNICATION

Chondroitinase ABC Treatment and the Phenotype of Neural Progenitor Cells Isolated From Injured Rat Spinal Cord

L. SLOVINSKÁ¹, I. NOVOTNÁ¹, D. ČÍŽKOVÁ¹

¹Institute of Neurobiology, Center of Excellence, Slovak Academy of Sciences, Košice, Slovakia

Received November 18, 2010

Accepted April 15, 2011

On-line May 16, 2011

Summary

The aim of the present study was to investigate whether enzyme chondroitinase ABC (ChABC) treatment influences the phenotype of neural progenitor cells (NPCs) derived from injured rat spinal cord. Adult as well as fetal spinal cords contain a pool of endogenous neural progenitors cells, which play a key role in the neuroregenerative processes following spinal cord injury (SCI) and hold particular promise for therapeutic approaches in CNS injury or neurodegenerative disorders. In our study we used *in vitro* model to demonstrate the differentiation potential of NPCs isolated from adult rat spinal cord after SCI, treated with ChABC. The intrathecal delivery of ChABC (10 U/ml) was performed at day 1 and 2 after SCI. The present findings indicate that the impact of SCI resulted in a decrease of all NPCs phenotypes and the ChABC treatment, on the contrary, caused an opposite effect.

Key words

Spinal cord injury • Enzyme chondroitinase ABC • Neural Progenitors cells

Corresponding author

L. Slovinská, Institute of Neurobiology, Slovak Academy of Sciences, CE, Šoltésovej 4-6, 040 01 Košice, Slovakia. E-mail: slovinska@saske.sk

Disorders of the central nervous system are a major concern in modern human society. Spinal cord injury (SCI) is a major cause of paralysis. Currently, there are no effective therapies to reverse this disabling condition. In the mammals, the adult neural tissues have limited regenerative capability. Neural progenitor cells (NPCs) refer to the multipotent cells that give rise to the

cells of the nervous system. They are found in both embryonic and adult tissues, in mammalian brain and spinal cord (Horner *et al.* 2000, Alvarez-Buylla *et al.* 2001), differentiating into neurons, astrocytes, oligodendrocytes. When NPCs are cultured in the presence of growth factors, they form neurospheres which are free-floating colonies of cells primarily composed of progenitor cells and <1 % stem cells (Morshead *et al.* 1994). NPCs play an important role in the neuroregenerative processes following spinal cord injury (SCI) and NPCs have been explored as a potential therapy for SCI (Willerth and Sakiyama-Elbert 2008). It is well documented that SCI initiates a chain of events that lead to cell death, scarring and the loss of function. The initial trauma injures cells, plasma endothelin-1 levels are elevated (Guo *et al.* 2010), the damaged cells release toxins that cause necrosis of the cells above and below the injury site. Subsequent events include the formation of a cystic cavity at the injury site, which becomes surrounded by a glial scar, composed of mainly reactive astrocytes (Fawcett and Asher 1999). The main class of inhibitory molecules produced by reactive astrocytes after SCI are chondroitin sulfate proteoglycans (CSPGs) (Fok-Seang *et al.* 1995). CSPGs are inhibitory molecules enriched in the extracellular matrix in the CNS that are upregulated at the injury site *in vivo* and their manipulation may be useful for treatment of human spinal injuries (Fitch and Silver 1997, Fawcett and Asher 1999, Tang *et al.* 2003). Furthermore, ChABC application promotes regeneration and restores function after SCI (Bradbury *et al.* 2002, Yick *et al.* 2003, Matsui and Oohira 2004, Sandvig *et al.* 2004, Huang *et al.* 2006)

Therefore, degradation of CSPG using enzyme chondroitinase ABC (ChABC) might impact the NPCs phenotype development at the lesion site.

Spinal progenitor cells were harvested from spinal cords of adult male Wistar rats weighting 290-320 g. All experiments conformed to the Slovak Law for Animal Protection No. 23/2009, which is transposed from the Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes and were approved by the Institutional Ethical Committee for animal research. Trauma was performed by modified balloon-compression technique (Vanicky *et al.* 2001) under isoflurane vapor inhalation anesthesia (1.5-3 %). A rectal probe was inserted, and body temperature was maintained at 37-38 °C using a heating pad. Animals were divided into 3 groups: i) naive rats, (n=5); ii) rats after SCI with IT application of saline (SCI+saline), (n=5); and iii) rats after SCI with intrathecal application (IT) of ChABC (10 U/ml, protease free, C3667, Sigma-Aldrich) (SCI+ChABC), (n=5). The IT delivery of ChABC or saline was performed at day 1 and 2 after SCI, according to IT application previously described (Cizkova *et al.* 2010). At the fifth day after SCI, NPCs were isolated from spinal cord. The dissected tissue of spinal cords was cut into small pieces and transferred to the papain dissociation system according to the Worthington kit protocol, to isolate neural stem cells. Harvested single cells were cultivated in Nunc T25 culture flasks, grown in proliferation culture medium composed of Dulbecco's Modified Eagle Medium (DMEM) and Ham's F12 (1/1 v/v) supplemented with 5 mg/ml streptomycin, 5 IU/ml penicillin, B27, N2 and growth factors FGF-2, bEGF (both 20 ng/ml) to allow for the formation of neurospheres (37 °C, 5 % CO₂). The arisen neurospheres that were formed within one week of *in vitro* cultivation, were dissociated by mechanical trituration and differentiated in growth factors free differentiation medium containing fetal bovine serum. The cultures were grown for additional 10 days to induce differentiation and then fixed for immunocytochemical detection in 15 wells of the 24-well plate per each group, 5 individual wells per each antibody, altogether 45 wells were analyzed. Immunocytochemistry was performed by applying primary antibodies for detection of astrocytes/anti-mouse GFAP (1:500), oligodendrocytes/anti-mouse RIP (1:1000) and neurons/anti-rabbit MAP2 (1:1000) (Table 1) followed with corresponding secondary fluorescence (FITC, CY3) antibodies.

To determine the number of differentiated

progeny (identified by specific cell phenotype) generated, the positive cells were counted as a percentage of total DAPI+ nuclei in 10 random fields. Data are presented as mean \pm S.E.M. Statistical differences between groups were evaluated with paired Student's t-test.

Table 1. Markers used in immunocytochemical analyses.

Marker	Specificity
MAP 2	microtubule associated protein 2, detects mature neurons
GFAP	glial fibrillary acidic protein, marker for astrocytes
RIP	receptor interacting protein, oligodendrocytes marker

Using immunocytochemistry by applying specific antibodies, the populations of neurons (MAP 2), astrocytes (GFAP) and oligodendrocytes (RIP) were analyzed (Fig. 1). The numbers of differentiated cells in SCI+saline vs. SCI+ChABC rats were: neurons 21.59 % vs. 24.57 %, astrocytes 11.10 % vs. 21.23 %, oligodendrocytes 26.45 % vs. 34.81 %. In naive rats we observed following values: neurons 28.47 %, astrocytes 15.1 % and oligodendrocytes 37.38 %.




Fig. 1. Comparison of the percentage of immunopositive cells derived from control-naive (white bars), SCI with IT application of saline (SCI+saline) (black bars) and SCI with IT application of ChABC (10 U/ml) (SCI+ChABC), (striped bars) animals. The impact of SCI resulted in decrease of all NPCs phenotypes. On the other side, application of the ChABC caused increase of all NPCs phenotypes.

In the present study we used an *in vitro* model demonstrating the differentiation potential of NPCs isolated from adult rat spinal cord after SCI and treatment with ChABC. Based on cultivation strategies and immunocytochemical analyses for cell markers (MAP 2,

GFAP, RIP) we were able to characterize the occurrence and representation of different cell types: neurons, astrocytes and oligodendrocytes derived from injured adult rat spinal cord treated with ChABC. These findings indicate, that the impact of SCI resulted in a decrease of NPCs phenotypes in general. On the contrary, the ChABC treatment caused an opposite effect, elevated numbers of surviving neurons and oligodendroglial cells, reaching almost control values, with acceleration of astrocytes. However, no significant differences between experimental and control groups were detected. These data partially corresponds with results of Sirko *et al.* (2007) who systematically addressed the question of whether ChABC affects stem cell behavior. They showed that the selective elimination of CSPGs with ChABC, both *in vivo* and *in vitro*, reduces NSCs proliferation and the differentiation of radial glia to neurons, whereas it favors the maturation of astrocytes. Removal of CSPGs severely impairs neurospheres formation, self-renewal and the generation of their neuronal progeny. This implies a role of CSPGs in the

regulation of growth and differentiation factors for NPCs. Although, our data confirm that ChABC delivery may enhance NPCs, particularly astrocytes and oligodendroglia, we did not detect differences in the ability of neurospheres formation between both groups. This may be due to the limited capacity of adult spinal cord tissue for neurosphere formation when compared with embryonic tissue (Davis and Temple 1994).

Conflict of Interest

There is no conflict of interest.

Acknowledgements

We express our thanks to Maria Spontakova for her great and valuable assistance in the immunocytochemical analysis. This study was supported by: VEGA 2-0019-08, 1-0674-09, 2/0114/11, COST BM 1002. These results were partially presented at the 4th Young Biomedical Engineers and Researchers Conference – YBERC 2010, held in Košice (Slovak Republic) on July 1-3, 2010.

References

- ALVAREZ-BUYLLA A, GARCIA-VERDUGO JM, TRAMONTIN AD: A unified hypothesis on the lineage of neural stem cells. *Nat Rev Neurosci* **2**: 287-293, 2001.
- BRADBURY EJ, MOON LDF, POPAT RJ, KING VR, BENNETT GS, PATEL PN, FAWCETT JW, McMAHON SB: Chondroitinase ABC promotes functional recovery after spinal cord injury. *Nature* **416**: 636-640, 2002.
- CIZKOVA D, NOVOTNA I, SLOVINSKA L, VANICKY I, JERGOVA S, ROSOCHA J, RADONAK J: Repetitive intrathecal catheter delivery of bone marrow mesenchymal stromal cells improves functional recovery in a rat model of contusive spinal cord injury. *J Neurotrauma* (in press) 2010.
- DAVIS AA, TEMPLE S: A self-renewing multipotential stem cell in embryonic rat cerebral cortex. *Nature* **372**: 263-266, 1994.
- FAWCETT JW, ASHER RA: The glial scar and central nervous system repair. *Brain Res Bull* **49**: 377-391, 1999.
- FITCH MT, SILVER J: Glial cell extracellular matrix: boundaries for axon growth in development and regeneration. *Cell Tissue Res* **290**: 379-384, 1997.
- FOK-SEANG J, SMITH-THOMAS LC, MEINERS S, MUIR E, DU JS, HOUSDEN E, JOHNSON AR, FAISSNER A, GELLER HM, KEYNES RJ: An analysis of astrocytic cell lines with different abilities to promote axon growth. *Brain Res* **689**: 207-223, 1995.
- GUO YF, REN AJ, CHEN DY, YUAN W, CHEN Y, GOU SH, JIA LS, YUAN WJ, LIU Y: Spinal cord injury blunted effects of endothelin-1 on Ca^{2+} transients and calcium current in isolated rat cardiomyocytes. *Physiol Res* **59**: 195-201, 2010.
- HORNER PJ, POWER AE, KEMPERMANN G, KUHN HG, PALMER TD, WINKLER J, THAL LJ, GAGE FH: Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. *J Neurosci* **20**: 2218-2228, 2000.
- HUANG WC, KUO WC, CHERNG JH, HSU SH, CHEN PR, HUANG SH, HUANG MC, LIU JC, CHENG H: Chondroitinase ABC promotes axonal re-growth and behavior recovery in spinal cord injury. *Biochem Biophys Res Commun* **349**: 963-968, 2006.
- MATSUI F, OOHIRA A: Proteoglycans and injury of the central nervous system. *Congenit Anom (Kyoto)* **44**: 181-188, 2004.

-
- MORSHEAD CM, REYNOLDS BA, CRAIG CG, MCBURNE MW, STAINES WA, MORASSUTTI D, WEISS S, VAN DER KOOY D: Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. *Neuron* **13**: 1071-1082, 1994.
- SANDVIG A, BERRY M, BARRETT LB, BUTT A, LOGAN A: Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon regeneration. *Glia* **46**: 225-251, 2004.
- SIRKO S, VON HOLST A, WIZENMANN A, GÖTZ M, FAISSNER A: Chondroitin sulfate glycosaminoglycans control proliferation, radial glia cell differentiation and neurogenesis in neural stem/progenitor cells. *Development* **134**: 2727-2738, 2007.
- TANG X, DAVIES JE, DAVIES SJ: Changes in distribution, cell associations, and protein expression levels of NG2, neurocan, phosphacan, brevican, versican V2, and tenascin-C during acute to chronic maturation of spinal cord scar tissue. *J Neurosci Res* **71**: 427-444, 2003.
- VANICKY I, URDZIKOVA L, SAGANOVA K, CIZKOVA D, GALIK J: A simple and reproducible model of spinal cord injury induced by epidural balloon inflation in the rat. *J Neurotrauma* **18**: 1399-1407, 2001.
- WILLERTH SM, SAKIYAMA-ELBERT SE: Cell therapy for spinal cord regeneration. *Adv Drug Deliv Rev* **60**: 263-276, 2008.
- YICK LW, CHEUNG PT, SO KF, WU W: Axonal regeneration of Clarke's neurons beyond the spinal cord injury scar after treatment with chondroitinase ABC. *Exp Neurol* **182**: 160-168, 2003.
-